Werkgroep Cardiologische centra Nederland

CORE 2 (Follow-up)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
Medicine
Olezarsen (ISIS 678354)
Population
ASCVD
Phase
III
Starting year
2022

Director of Study

drs. K.W. Wu (Cardioloog)
Dirksland, Van Weel-Bethesda Ziekenhuis